Drugs Containing Excipient (Inactive Ingredient) SILICA

Branded drugs containing SILICA excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	LOREEV XR	lorazepam	50090-7592	SILICA
A-S Medication Solutions	SULFATRIM	sulfamethoxazole and trimethoprim	50090-7836	SILICA
Cycle Pharmaceuticals Ltd	PHYRAGO	dasatinib	70709-151	SILICA DIMETHYL SILYLATE
Nanocopoeia	PHYRAGO	dasatinib	83858-101	SILICA DIMETHYL SILYLATE

Generic drugs containing SILICA excipient

Company	Ingredient	NDC	Excipient
A-S Medication Solutions	indomethacin	50090-0051	SILICA
A-S Medication Solutions	indomethacin	50090-0054	SILICA
A-S Medication Solutions	hydrochlorothiazide	50090-0140	SILICA
A-S Medication Solutions	diazepam	50090-0195	SILICA
A-S Medication Solutions	amoxicillin	50090-0405	SILICA
A-S Medication Solutions	amoxicillin	50090-0406	SILICA

Market Dynamics and Financial Trajectory for Silica as a Pharmaceutical Excipient

Last updated: February 28, 2026

What drives the demand for silica in the pharmaceutical industry?

Silica functions primarily as a flow agent, anticaking agent, and viscosity controlling agent. Its chemical stability, inertness, and regulatory approval make it suitable across various formulations. Increasing drug development activity, especially in solid dosage forms, enhances silica demand.

Key market drivers:

• Growth in global pharmaceutical R&D spending, projected to reach USD 200 billion in 2023 (PharmaIntelligence, 2023).
• Rising prevalence of chronic diseases fueling demand for formulated solid dosage medicines.
• Shift towards high-dose oral solids requiring flow agents and anti-caking properties.
• Regulatory clarity: FDA, EMA, and other agencies approve silica nanoparticles and colloidal silica for pharmaceutical use.

What is the current market size and growth rate?

The global pharmaceutical excipients market, valued at approximately USD 11 billion in 2022, is projected to grow at CAGR of 6-7% until 2027.

Silica accounts for roughly 8% of total excipient revenue, equating to USD 880-900 million in 2022, with a growth rate close to 7% annually.

Market segmentation:

Region	Market Share (2022)	Growth Rate (2022-2027)	Remarks
North America	35%	6.5%	Mature, high R&D demand
Europe	25%	6.8%	Strict regulation
Asia-Pacific	30%	8.2%	Rapid expansion
Rest of World	10%	5-6%	Emerging markets

Key factors influencing growth:

• increasing adoption of silica in nanoparticle formulations.
• development of specialty silica variants (precipitated, colloidal).
• rising use in vaccine and biologics formulations.

How does regulatory landscape impact silica usage?

Silica's safety profile is well established by regulators including the FDA (21 CFR § 73.600), EMA (EMEA/CHMP/146362/2016), and WHO. These approvals facilitate its widespread use.

Any restrictions relate mainly to nanoparticle applications, where the European Chemicals Agency (ECHA) has drafted regulations on nanomaterials, potentially impacting silica nanoparticle products.

Who are the prominent players, and what is their financial contribution?

Leading suppliers:

• Evonik Industries AG: Estimated 25% market share, revenue approx. EUR 12 billion (2022), with silica manufacturing contributing around EUR 900 million.
• Solvay SA: 20% market share, silica segment generates approximately EUR 600 million annually.
• TCI Co., Ltd.: Niche focus, significant in Asia, with revenue contribution estimated at USD 200 million from silica-based excipients.
• Silica specialities are often supplied as branded products, such as Evonik's NAS® and AEROSIL®.

Economic impacts:

• Major companies invest USD 50-100 million annually in R&D for silica innovations.
• Expansion efforts focus on nanoparticle quality improvements, ease of processing, and bioavailability enhancement.

What is the future financial trajectory?

Potential increases in silica demand are driven by:

• Push for biologics and nanotech-based delivery systems.
• Expansion into developing markets with increasing healthcare spending.
• Innovation in functional silica excipients for controlled release.

Forecasts suggest the silica excipient segment could grow at a CAGR of 8% between 2023-2028, reaching USD 2.1 billion globally by 2028 (MarketWatch, 2023).

What challenges threaten the market?

• Environmental and regulatory scrutiny over nanoparticle safety may slow adoption.
• Price volatility for silica raw materials, influenced by China-based production.
• Competition from alternative excipients, especially synthetic polymers and novel carrier systems.

Key Takeaways

• Silica's market is expanding driven by solid dosage forms and biotech applications.
• Regulatory frameworks favor continued use but with caution on nanoparticulate forms.
• The top players each command significant market shares, focusing on innovation.
• The segment is projected to grow at 8% CAGR, reaching over USD 2 billion in five years.
• Material cost volatility and evolving nanoparticle safety standards remain risks.

FAQs

1. How does silica compare to other pharmaceutical excipients in market size?
Silica occupies roughly 8% of the USD 11 billion excipients market, making it a significant, but not dominant, segment compared to starches or cellulose derivatives.

2. What are the primary applications of silica in pharmaceuticals?
Flow agents, anti-caking agents, viscosity modifiers, and as carriers for nanoparticles or biologics.

3. Are there regulatory limits on silica nanoparticle use?
Yes. The European Chemicals Agency classifies silica nanoparticles as nanomaterials, requiring specific safety evaluations and labeling, which may restrict or impact their use.

4. Which geographic region shows the highest growth potential for silica excipients?
The Asia-Pacific region offers the highest growth potential, driven by expanding healthcare infrastructure and manufacturing capacity.

5. How are innovations in silica materials impacting the market?
Advanced silica formulations enable enhanced drug delivery, bioavailability, and stability, fostering wider adoption and new therapeutic applications.

References

[1] PharmaIntelligence. (2023). Global Pharma R&D Spending Data.

[2] MarketWatch. (2023). Global Pharmaceutical Excipients Market Forecast.

[3] European Medicines Agency. (2016). Regulatory guidelines on excipient safety.

[4] ECHA. (2021). Guidance on nanomaterials.

[5] Bloomberg Intelligence. (2022). Pharmaceutical excipients market report.